Aikema Medical Secures RMB 50 Million Additional Investment to Advance Pulsed Field Ablation and 3D Mapping Systems for Arrhythmia Treatment

Investment Circle (ID: pedaily2012) June 17 News: AccuPulse Medical Technology Co., Ltd. (referred to as "AccuPulse")AccuPulse") recently announced the completionBlue Bay Sci-Tech GroupAccuPulse Medical Technology Co., Ltd. Secures Additional RMB 50 Million in Investment. This round of financing will still be used to advance the research and development and commercial operation of the company's core products, the pulsed field ablation and 3D mapping systems. It is reported that in February this year, the company completed a fund raising managed by Shanghai BioPharmaceutical Fund and Shaoxing Binhai New District BioPharmaceutical Industry Equity Investment Fund managed by Shengshi Investment.The nearly 200 million yuan A+ round of financing was co-led.

AccuPulse Medical Technology Co., Ltd. was founded in November 2020. It is committed to the innovative platform technology in the field of cardiac electrophysiology. The company has assembled a research and development team led by well-known electrophysiology technology experts from the United States and has received strong support from returning overseas scientists, renowned clinical experts, and venture capital institutions. Its R&D centers are located in Suzhou and the United States.

AccuPulse has established nearly 10 product pipelines based on new technologies such as pulsed field ablation (PFA) and innovative 3D mapping, covering the complete process of diagnosis and treatment for atrial fibrillation, premature ventricular contractions, and other arrhythmia ablations. In April 2023, AccuPulse's self-developed pulsed field ablation system successfully completed all clinical study enrollments, placing it in the first tier of pulsed field product clinical research both domestically and internationally. It is planned to be launched simultaneously with AccuPulse’s self-developed cardiac 3D mapping system in 2025.

The AccuPulse pulsed ablation system, independently developed by AccuPulse Medical, is designed with a feature that provides feedback on the contact between the catheter and the myocardium. This helps doctors assess the contact status between the catheter tip and the target tissue. Additionally, the system includes an adjustable loop diameter at the catheter tip to accommodate pulmonary veins of different sizes, while also being compatible with currently used 3D mapping systems in clinical practice. In February this year, the system entered the special review channel for innovative medical devices and is about to enter the registration approval stage in the near future.

It is reported that the system has been clinically studied by 18 electrophysiology experts across 8 research centers in China, achieving a 100% immediate success rate during procedures. Currently, the 12-month long-term follow-up shows an effectiveness rate of 87.7%, with significant improvement in patients' quality of life post-operation.

For obtaining this round of financing,Founder of AccuPulse MedicalSaid: "Thanks to Lanwan Technology Group and all the old shareholders for their recognition and continuous support of AccuPulse. We are greatly honored to be favored by these 'patient capitals' with foresight and courage, and we also feel a great sense of responsibility. We firmly believe that pulsed field ablation combined with 3D mapping systems is the future direction of electrophysiology technology development. The AccuPulse team will continue on the path of disruptive innovation and internationalization, bringing better solutions to patients with arrhythmia and creating greater value for shareholders."

Deng Jianxin, Founder of Blue Bay Innovation GroupAccuPulse has strong innovation capabilities and an excellent team. The market prospects for the application of PFA in atrial fibrillation treatment are broad. With the company's outstanding clinical data for its PFA product and the support of its three-dimensional mapping system, it is expected that the company will possess strong competitiveness. We have full confidence in the AccuPulse team led by Mr. Yin, and believe that AccuPulse will grow into a representative of China's innovative medical device enterprises with international competitiveness.